ଏରିଥ୍ରୋମାଇସିନ

ଏରିଥ୍ରୋମାଇସିନ
Clinical data
Trade names	Eryc, Erythrocin, others
AHFS/Drugs.com	monograph
MedlinePlus	a682381
Pregnancy; category	AU: A ; US: B (No risk in non-human studies) ; ;
Routes of; administration	oral, iv, im, topical, eye drops
ATC code	D10AF02 (WHO) J01FA01 S01AA17 QJ51FA01 (WHO);
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	Depends on the ester type between 30% - 65%
Protein binding	90%
Metabolism	liver (under 5% excreted unchanged)
Elimination half-life	1.5 hours
Excretion	bile
Identifiers
	IUPAC name (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-; {[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-; 14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-; 5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-; 3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione;
CAS Number	114-07-8 ;
PubChem CID	3255;
IUPHAR/BPS	1456;
DrugBank	DB00199 ;
ChemSpider	12041 ;
UNII	63937KV33D;
KEGG	D00140 ;
ChEBI	CHEBI:42355 ;
ChEMBL	CHEMBL532 ;
ECHA InfoCard	100.003.673
Chemical and physical data
Formula	C37H67NO13
Molar mass	୭୩୩.୯୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O;
	InChI InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1 ; Key:ULGZDMOVFRHVEP-RWJQBGPGSA-N ;
(verify)

ଏରିଥ୍ରୋମାଇସିନ ଏକ ଆଣ୍ଟିବାୟୋଟିକ ଯାହା ଅନେକ ସଂଖ୍ୟକ ଜୀବାଣୁ ସଂକ୍ରମଣ ଚିକିତ୍ସା ନିମନ୍ତେ ବ୍ୟବ‌ହାର କରାଯାଏ । ^[୨] ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ଚର୍ମ ସଂକ୍ରମଣ, କ୍ଲାମିଡିଆ ସଂକ୍ରମଣ ଓ ସିଫିଲିସ ଆଦି ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ଏରିଥ୍ରୋମାଇସିନ ଦିଆଯାଏ । ଗର୍ଭାବସ୍ଥାରେ ଏହା ଭବିଷ୍ୟତ ନବଜାତ ଶିଶୁର ଗ୍ରୁପ ବି ସ୍ଟ୍ରେପ୍ଟୋକୋକାଲ ସଂକ୍ରମଣ ନ ହେବା ନିମନ୍ତେ ପ୍ରତିଷେଧ ଭାବରେ ଦିଆଯାଏ ।^[୨] ପାକସ୍ଥଳୀରୁ ଖାଦ୍ୟ ନିଷ୍କାସନ ବିଳମ୍ବ ହେଉଥିଲେ ଏରିଥ୍ରୋମାଇସିନ ଦିଆଯାଏ । ^[୩] ଏହା ଶୀରାରେ ଓ ପାଟିବାଟେ ଦିଆଯାଏ । ^[୨] ନବଜାତ ଶିଶୁର ଆଖି ସଂକ୍ରମଣ ପ୍ରତିରୋଧ କରିବା ନିମନ୍ତେ ଏରିଥ୍ରୋମାଇସିନ ଥିବା ଏକ ଆଖି-ମଲମ ରୁଟିନ ହିସାବରେ ଦେବାକୁ ସୁପାରିସ କରାଯାଏ । ^[୪]

ଏରିଥ୍ରୋମାଇସିନ ଔଷଧର ମୂଖ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାମାନଙ୍କର ନାମ: ପେଟ କ୍ରାମ୍ପ, ବାନ୍ତି ଓ ତରଳ ଝାଡ଼ା । ଗମ୍ଭୀର ପାର୍ଶ୍ୱା ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ କ୍ଲସ୍ଟ୍ରିଡିଅନ ଡିଫିସିଲ କୋଲାଇଟିସ, ଯକୃତ ସମସ୍ୟା, ଲମ୍ବା କ୍ୟୁଟି ଓ ଆଲର୍ଜି ଇତ୍ୟାଦି ପ୍ରଧାନ । ପେନିସିଲିନ ଆଲର୍ଜି ଥିବା ଲୋକଙ୍କନମନ୍ତେ ଏହା ବିପଦମୁକ୍ତ ।^[୨] ଏରିଥ୍ରୋମାଇସିନ ଗର୍ଭାବସ୍ଥା ଓ ସ୍ତନ୍ୟପାନ ସମୟରେ ମଧ୍ୟ ଏରିଥ୍ରୋମାଇସିନ ବିପଦମୁକ୍ତ ।^[୧]^[୫] ମାକ୍ରୋଲାଇଡ଼ ପରିବାରର ସଦସ୍ୟ ଏରିଥ୍ରୋମାଇସିନ ଜୀବାଣୁର ପ୍ରୋଟିନ ତିଆରି କମେଇଦିଏ ।^[୨]

ସାକାରୋପଲିସ୍ପୋରେ ଏରିଥ୍ରି ଜୀବାଣୁରୁ ଏରିଥ୍ରୋମାଇସିନ ସନ ୧୯୫୨ରେ ପ୍ରଥମେ ପୃଥକ କରାଯାଇଥିଲା ।^[୨]^[୬] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ ଅଛି ଯାହା ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୭]ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ ଉପଲବ୍‌ଧ ହୁଏ ଓ ଦାମିକା ନୁହେଁ ।^[୫] ବଟିକା ପିଛା ହୋଲସେଲ ମୂଲ୍ୟ ୦.୦୩ରୁ ୦.୦୬ ଆମେରିକୀୟ ଡଲାର ।^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Prescribing medicines in pregnancy database". Australian Government. August 23, 2015.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Erythromycin". The American Society of Health-System Pharmacists. Retrieved Aug 1, 2015.
↑ "Clinical guideline: management of gastroparesis". The American Journal of Gastroenterology. 108 (1): 18–37, quiz 38. Jan 2013. doi:10.1038/ajg.2012.373. PMID 23147521. {{cite journal}}: Cite uses deprecated parameter |authors= (help)
↑ "Treatment and prevention of ophthalmia neonatorum". Canadian Family Physician Médecin De Famille Canadien. 59 (11): 1187–90. Nov 2013. PMID 24235191. {{cite journal}}: Cite uses deprecated parameter |authors= (help)
↑ ^୫.୦ ^୫.୧ Hamilton, Richard J. (2013). Tarascon pocket pharmacopoeia (2013 delux lab-coat ed., 14th ed. ed.). [Sudbury, Mass.]: Jones & Bartlett Learning. p. 72. ISBN 9781449673611. {{cite book}}: |edition= has extra text (help); Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
↑ Vedas, J. C. (2000). Biosynthesis : polyketides and vitamins. Berlin [u.a.]: Springer. p. 52. ISBN 9783540669692. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
↑ "WHO Model List of Essential Medicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
↑ "Erythromycin". International Drug Price Indicator Guide. Retrieved 23 August 2015.^{[permanent dead link]}

[AG2015-1] ୧.୦ ^୧.୧ "Prescribing medicines in pregnancy database". Australian Government. August 23, 2015.

[AHFS2015-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Erythromycin". The American Society of Health-System Pharmacists. Retrieved Aug 1, 2015.

[3] "Clinical guideline: management of gastroparesis". The American Journal of Gastroenterology. 108 (1): 18–37, quiz 38. Jan 2013. doi:10.1038/ajg.2012.373. PMID 23147521. {{cite journal}}: Cite uses deprecated parameter |authors= (help)

[4] "Treatment and prevention of ophthalmia neonatorum". Canadian Family Physician Médecin De Famille Canadien. 59 (11): 1187–90. Nov 2013. PMID 24235191. {{cite journal}}: Cite uses deprecated parameter |authors= (help)

[Ric2013-5] ୫.୦ ^୫.୧ Hamilton, Richard J. (2013). Tarascon pocket pharmacopoeia (2013 delux lab-coat ed., 14th ed. ed.). [Sudbury, Mass.]: Jones & Bartlett Learning. p. 72. ISBN 9781449673611. {{cite book}}: |edition= has extra text (help); Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[6] Vedas, J. C. (2000). Biosynthesis : polyketides and vitamins. Berlin [u.a.]: Springer. p. 52. ISBN 9783540669692. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[7] "WHO Model List of Essential Medicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[ERC2015-8] "Erythromycin". International Drug Price Indicator Guide. Retrieved 23 August 2015.^{[permanent dead link]}

[୨]

[୩]

[୪]

[୧]

[୫]

[୬]

[୭]

[୮]

Clinical data


Trade names	Eryc, Erythrocin, others^[୨]
AHFS/Drugs.com	monograph
MedlinePlus	a682381
Pregnancy category	AU: A ^[୧] US: B (No risk in non-human studies) ^[୨]
Routes of administration	oral, iv, im, topical, eye drops
ATC code	D10AF02 (WHO) J01FA01 S01AA17 QJ51FA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	Depends on the ester type between 30% - 65%
Protein binding	90%
Metabolism	liver (under 5% excreted unchanged)
Elimination half-life	1.5 hours
Excretion	bile
Identifiers
IUPAC name (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6- {[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}- 14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)- 5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}- 3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
CAS Number	114-07-8^Y
PubChem CID	3255
IUPHAR/BPS	1456
DrugBank	DB00199^Y
ChemSpider	12041^Y
UNII	63937KV33D
KEGG	D00140^Y
ChEBI	CHEBI:42355^Y
ChEMBL	CHEMBL532^Y
ECHA InfoCard	100.003.673
Chemical and physical data
Formula	C₃₇H₆₇NO₁₃
Molar mass	୭୩୩.୯୪ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
InChI InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1^Y Key:ULGZDMOVFRHVEP-RWJQBGPGSA-N^Y
(verify)